Stay updated with breaking news from Michael Klichinsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Carisma Therapeutics (NASDAQ:CARM – Get Rating) was upgraded by stock analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a $7.00 price objective on the stock. Jefferies Financial Group’s price target would indicate a potential upside of […]
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
HC Wainwright reissued their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM – Get Rating) in a research note released on Wednesday morning, Marketbeat.com reports. They currently have a $10.00 target price on the stock. HC Wainwright also issued estimates for Carisma Therapeutics’ Q2 2023 earnings at ($0.66) EPS, Q3 2023 earnings at ($0.71) EPS, […]
Carisma Therapeutics (NASDAQ:CARM – Get Rating) and Synaptogenix (NASDAQ:SNPX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability. Valuation & Earnings This table compares Carisma Therapeutics and Synaptogenix’s […]
Carisma Therapeutics (NASDAQ:CARM – Get Rating) will be posting its quarterly earnings results on Friday, May 12th. Carisma Therapeutics Stock Up 2.7 % Shares of CARM stock traded up $0.16 on Thursday, hitting $6.02. 84,394 shares of the stock were exchanged, compared to its average volume of 117,782. The company has a market capitalization of […]